ERGO OTC
Entia Biosciences, Inc.
1W: +25.0%
1M: +25.0%
3M: +400.0%
YTD: +233.3%
1Y: +900.0%
3Y: -96.9%
5Y: -85.1%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$715K
-33.3% ▼
Capital Expenditures
$7K
+66.6% ▲
5Y CAGR: -30.5%
Free Cash Flow
-$722K
-29.5% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$52K
+168.9% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$1M | -$3M | -$2M | -$2M | -$1M |
| Depreciation & Amort. | $22K | $36K | $38K | $32K | $18K |
| Stock-Based Comp. | $485K | $1M | $643K | $590K | $110K |
| Change in Working Capital | $310K | $613K | $579K | $829K | $482K |
| Other Non-Cash Items | $23K | $2M | $790K | $814K | $26K |
| Operating Cash Flow | -$315K | -$767K | -$680K | -$537K | -$715K |
| — Investing Activities — | |||||
| Capital Expenditures | -$63K | -$65K | -$45K | -$21K | -$7K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | -$46 | -$12 | -$41 | -$13 | -$7 |
| Investing Cash Flow | -$63K | -$65K | -$45K | -$21K | -$7K |
| — Financing Activities — | |||||
| Net Debt Issuance | $47K | $154K | $523K | -$78K | $774K |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | $701K | $265K | $560K | $0 |
| Financing Cash Flow | $374K | $855K | $788K | $483K | $774K |
| Net Change in Cash | -$4K | $24K | $63K | -$75K | $52K |
| Cash End of Period | $13K | $37K | $99K | $24K | $76K |
| Free Cash Flow | -$378K | -$831K | -$726K | -$558K | -$722K |